Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07187531 · ClinicalTrials.gov registry record · Phase 2

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

A Phase 2 study of Type 1 Diabetes, sponsored by SAb Biotherapeutics.

Recruiting
Registry status
Phase 2
Development phase
159
Enrollment target
20
Study locations

NCT07187531 is a Phase 2 study of Type 1 Diabetes that is actively recruiting participants, run by SAb Biotherapeutics. The registered enrollment target is 159 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07187531, a Phase 2 study of Type 1 Diabetes, is actively recruiting participants, sponsored by SAb Biotherapeutics.

RECRUITING
Registry status
Phase 2
Development phase
159 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

Conditions Studied

Type 1 Diabetes

Interventions

  • OTHER Placebo
  • DRUG High Dose SAB-142
  • DRUG Low Dose SAB-142

Study Locations (20)

Other

  • Queensland Children's Hospital - Brisbane
  • Government of Western Australia - Child and Adolescent Health Service - Perth Children's Hospital - Nedlands
  • The Royal Children's Hospital Melbourne - Parkville

Florida

  • University of Florida College of Medicine - Gainesville
  • University of Miami - Gables One Tower - Miami

Texas

  • Cook Children's Medical Center - Fort Worth
  • Texas Children's Hospital - Clinical Care Center - Pediatric Renal Clinic - Houston

Washington

  • Benaroya Research Institute at Virginia Mason - Seattle
  • Mary Bridge Children's Outpatient Center - Tacoma - Tacoma

California

  • University of California San Francisco Benioff Children's Hospital - San Francisco

Colorado

  • University of Colorado - Barbara Davis Center for Diabetes - Aurora

Georgia

  • Children's Healthcare of Atlanta (CHOA) - Center for Advanced Pediatrics - Atlanta

Indiana

  • IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology - Indianapolis

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2025-11-25
Est. Completion 2028-12
Phase Phase 2

Sponsor

SAb Biotherapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07187531

The ClinicalTrials.gov registry entry for NCT07187531 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (81% lower). The listed sponsor is SAb Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07187531 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07187531 about?

NCT07187531 is a clinical study titled "SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes". This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

What is the current status of trial NCT07187531?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2025-11-25. Estimated completion is 2028-12.

What conditions does trial NCT07187531 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT07187531?

The interventions under investigation include: Placebo (OTHER), High Dose SAB-142 (DRUG), Low Dose SAB-142 (DRUG).

Who is sponsoring clinical trial NCT07187531?

This trial is sponsored by SAb Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07187531 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.